Edition:
United States

Rxi Pharmaceuticals Corp (RXII.OQ)

RXII.OQ on NASDAQ Stock Exchange Capital Market

0.63USD
25 Jul 2017
Change (% chg)

$0.00 (+0.70%)
Prev Close
$0.63
Open
$0.63
Day's High
$0.66
Day's Low
$0.63
Volume
24,685
Avg. Vol
80,128
52-wk High
$2.92
52-wk Low
$0.51

Latest Key Developments (Source: Significant Developments)

RXI Pharma completes enrollment of Phase 1/2 trial with RXI-109
Wednesday, 21 Jun 2017 07:05am EDT 

June 21 (Reuters) - RXI Pharmaceuticals Corp ::RXI Pharmaceuticals announces completion of enrollment of Phase 1/2 clinical trial with RXI-109 for retinal scarring.RXI Pharmaceuticals Corp - RXI-109 has been well tolerated with no drug related issues occurring to date.  Full Article

RXI Pharmaceuticals announces initiation of its consumer testing program with RXI-231
Monday, 12 Jun 2017 07:05am EDT 

June 12 (Reuters) - Rxi Pharmaceuticals Corp :RXI Pharmaceuticals Corp- rxi pharmaceuticals announces initiation of its consumer testing program with rxi-231.RXI Pharmaceuticals - ‍initiation of consumer/functional testing program with rxi-231, cosmetic ingredient based on sd-rxrna that targets tyrosinase​.RXI Pharmaceuticals Corp - ‍consumer testing program will evaluate use and consumer acceptability of rxi-231​.RXI Pharmaceuticals - anticipate duration of combined studies under this program to be about 3-4 months enabling us to report results in q4 of this year.  Full Article

Rxi Pharmaceuticals posts Q1 loss per share $0.27
Thursday, 11 May 2017 07:05am EDT 

May 11 (Reuters) - Rxi Pharmaceuticals Corp :Rxi Pharmaceuticals reports first quarter 2017 financial results and recent corporate highlights.Qtrly loss per share $0.27.Rxi Pharmaceuticals Corp - at March 31, 2017, company had cash of $10.2 million, compared with $12.9 million at December 31, 2016.  Full Article

Rxi Pharmaceuticals reports Q4 loss per share $0.60
Thursday, 30 Mar 2017 07:02am EDT 

Rxi Pharmaceuticals Corp : Rxi Pharmaceuticals reports fourth quarter and year end 2016 financial results and recent corporate highlights . Believes that its existing cash should be sufficient to fund operations for at least next twelve months . Qtrly loss per share $0.60 .Rxi Pharmaceuticals Corp - research and development expense for quarter was $1.3 million compared with $1.7 million.  Full Article

RXi Pharmaceuticals CEO Cauwenbergh buys 10,000 shares of co's common stock on Jan 19
Thursday, 19 Jan 2017 01:54pm EST 

RXi Pharmaceuticals Corp :RXi Pharmaceuticals Corp CEO Geert Cauwenbergh reports purchase of 10,000 shares of co's common stock on Jan 19 - SEC filing.  Full Article

RXi Pharmaceuticals enters into exclusive option agreement to acquire Mirimmune Inc
Wednesday, 12 Oct 2016 07:02am EDT 

RXi Pharmaceuticals Corp : RXi Pharmaceuticals enters into exclusive option agreement to acquire Mirimmune Inc . RXi Pharmaceuticals Corp - can exercise option to acquire Mirimmune on terms set forth in option agreement at any time prior to April 5, 2017 . RXi Pharmaceuticals Corp - deal for number of shares equal to 19.99% of then outstanding shares of common stock of RXi . RXi Pharmaceuticals Corp - entered into an option agreement to acquire all outstanding capital stock of Mirimmune Inc .RXi Pharmaceuticals Corp - deal also provides for additional potential consideration contingent on Mirimmune reaching certain milestones.  Full Article

RXI Pharmaceuticals Qtrly loss per share $0.34
Thursday, 11 Aug 2016 07:02am EDT 

RXI Pharmaceuticals Corp : RXI Pharmaceuticals reports second quarter 2016 financial results and highlights recent corporate developments .Net revenue for quarter ended june 30, 2016 was $9,000 as compared with no revenues for quarter ended june 30, 2015.  Full Article

Rxi Pharmaceuticals reports Q1 loss of $0.34 per share
Thursday, 12 May 2016 07:40am EDT 

Rxi Pharmaceuticals Corp : Qtrly loss per share $0.34 . Believes existing cash, cash equivalents and short-term investments should be sufficient to fund operations for at least one year .Rxi pharmaceuticals reports first quarter 2016 financial results and highlights recent corporate developments.  Full Article

RXi Pharmaceuticals announces positive results with RNAi platform
Tuesday, 20 Oct 2015 07:02am EDT 

RXi Pharmaceuticals:Announces positive results with RNAi platform.Says potent reduction of long non-coding rnas demonstrated in collaboration with Biogazelle.Says considering Rxi's self-delivering platform for therapeutic applications in the future.  Full Article

RXi Pharmaceuticals reports positive interim results in mid-stage dermatology program with Rxi-109
Thursday, 15 Oct 2015 07:02am EDT 

RXi Pharmaceuticals:Reports positive interim results in mid-stage dermatology program with Rxi-109.Says both dose levels of Rxi-109 were equally well tolerated.  Full Article